MUPIROCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mupirocin, and what generic alternatives are available?
Mupirocin is a drug marketed by Alembic, Amneal, Encube, Glenmark Pharms Inc, Padagis Israel, Taro, Fougera Pharms, Glenmark Pharms, and Teva. and is included in eleven NDAs.
The generic ingredient in MUPIROCIN is mupirocin. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the mupirocin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mupirocin
A generic version of MUPIROCIN was approved as mupirocin by PADAGIS ISRAEL on November 7th, 2003.
Summary for MUPIROCIN
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 25 |
Raw Ingredient (Bulk) Api Vendors: | 87 |
Clinical Trials: | 81 |
Patent Applications: | 5,308 |
Drug Prices: | Drug price information for MUPIROCIN |
Drug Sales Revenues: | Drug sales revenues for MUPIROCIN |
DailyMed Link: | MUPIROCIN at DailyMed |
Recent Clinical Trials for MUPIROCIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Jiangxi Provincial Cancer Hospital | Phase 3 |
Future University in Egypt | Phase 2/Phase 3 |
Nantes University Hospital | Phase 2 |
Pharmacology for MUPIROCIN
Drug Class | RNA Synthetase Inhibitor Antibacterial |
Mechanism of Action | RNA Synthetase Inhibitors |
Medical Subject Heading (MeSH) Categories for MUPIROCIN
Anatomical Therapeutic Chemical (ATC) Classes for MUPIROCIN
US Patents and Regulatory Information for MUPIROCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alembic | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 213053-001 | Nov 16, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Fougera Pharms | MUPIROCIN | mupirocin | OINTMENT;TOPICAL | 065192-001 | Nov 30, 2005 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Glenmark Pharms Inc | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 201587-001 | Jan 24, 2013 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Glenmark Pharms | MUPIROCIN | mupirocin | OINTMENT;TOPICAL | 090480-001 | Jun 8, 2011 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Amneal | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 214811-001 | Nov 15, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |